As Per Financial Statement (Zenith Capital Corp.) Page 7:

Notes to the Consolidated Financial Statements
For the years ended April 30, 2021 and 2020
(Tabular amounts in thousands of US dollars, except for number of shares)


"1. General information
Zenith Capital Corp. is a company domiciled in Canada and was incorporated under the Business Corporations Act (Alberta) on
April 10, 2013. On May 24, 2013, 1741273 Alberta Ltd. changed its name to Zenith Epigenetics Corp. On August 1, 2016, Zenith
Epigenetics Corp. changed its name to Zenith Capital Corp. concurrent with an internal corporate reorganization. The reorganization resulted in the transfer of Zenith Capital Corp.’s principal operating assets to Zenith Epigenetics Ltd., a wholly-owned subsidiary, in exchange for additional common shares of Zenith Epigenetics Ltd. Zenith Capital Corp. retained its investment in the royalty preferred shares of Resverlogix Corp. (“Resverlogix”). Resverlogix and Zenith have a majority of their directors in common, and thus are considered related parties. As Zenith Capital Corp. owns all of the securities of Zenith Epigenetics Ltd., the reorganization did not result in a change in the ultimate beneficial ownership of the operating assets.

The consolidated financial statements comprise Zenith Capital Corp. and its wholly-owned subsidiaries, Zenith Epigenetics Ltd.
and Zenith Epigenetics Inc. (together referred to as the “Company”, “Zenith” or the “Group”). Zenith Capital Corp. and Zenith
Epigenetics Ltd. are incorporated under the laws of Alberta. Zenith Epigenetics Inc. is incorporated under the laws of Delaware.
The Company has offices located at Suite 300, 4820 Richard Road S.W., Calgary, Alberta, T3E 6L1, and at Suite 4010, 44
Montgomery Street, San Francisco, 94104. The registered and records office is located at Suite 600, 815 - 8th Avenue S.W.,
Calgary, Alberta, T2P 3P2.

Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd. is a clinical stage biotechnology company
developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet
medical need. Zenith’s epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective
BET inhibitors. Zenith’s goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies."

Koo